183,110 Shares of CeriBell, Inc. $CBLL Purchased by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC bought a new stake in shares of CeriBell, Inc. (NASDAQ:CBLL) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 183,110 shares of the company’s stock, valued at approximately $4,466,000. Lisanti Capital Growth LLC owned approximately 0.48% of CeriBell as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of CeriBell in the 2nd quarter worth about $37,657,000. Bank of New York Mellon Corp purchased a new stake in CeriBell in the second quarter worth approximately $17,437,000. TimesSquare Capital Management LLC purchased a new stake in CeriBell during the second quarter valued at $15,182,000. KCM Capital Inc increased its position in shares of CeriBell by 40.0% during the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock valued at $25,662,000 after purchasing an additional 400,000 shares during the last quarter. Finally, Bank of America Corp DE purchased a new position in shares of CeriBell during the 2nd quarter worth $4,619,000.

Insider Transactions at CeriBell

In related news, CFO Scott Blumberg sold 33,512 shares of CeriBell stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $25.03, for a total value of $838,805.36. Following the sale, the chief financial officer owned 148,121 shares of the company’s stock, valued at approximately $3,707,468.63. This trade represents a 18.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP David Foehr sold 9,255 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $24.25, for a total transaction of $224,433.75. Following the transaction, the vice president owned 34,144 shares of the company’s stock, valued at approximately $827,992. This trade represents a 21.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 176,897 shares of company stock worth $4,415,969. Insiders own 17.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on CBLL shares. BTIG Research reiterated a “buy” rating on shares of CeriBell in a research report on Wednesday, November 4th. Canaccord Genuity Group raised their target price on shares of CeriBell from $26.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. Barclays raised CeriBell to a “neutral” rating in a report on Tuesday, August 18th. TD Cowen increased their price target on shares of CeriBell from $29.00 to $33.00 and gave the company a “buy” rating in a report on Friday, October 2nd. Finally, Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, CeriBell currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.25.

CeriBell Stock Performance

Shares of CBLL stock opened at $27.80 on Thursday. CeriBell, Inc. has a 1 year low of $12.36 and a 1 year high of $28.89. The business has a fifty day moving average of $25.46 and a 200 day moving average of $21.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 8.18 and a quick ratio of 7.79. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -14.33 and a beta of 0.86.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). The business had revenue of $29.34 million during the quarter, compared to analysts’ expectations of $29.18 million. CeriBell had a negative net margin of 67.96% and a negative return on equity of 52.59%. As a group, research analysts expect that CeriBell, Inc. will post -2.05 earnings per share for the current year.

CeriBell Profile

Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.